So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper… The U.S. Food and Drug Administration (FDA) has approved ...

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab). Lecanemab was authorised by the MHRA for ...

— Recommendations are independently chosen by our editors. Purchases you make through our links may earn us and our publishing partners a commission.

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for early Alzheimer’s disease (AD). Nonetheless, Japanese drugmaker Eisai (TYO: ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and ...

Lecanemab (brand name Leqembi, manufactured by Eisai) is the first disease modifying drug for Alzheimer’s disease. It is a monoclonal antibody that binds to aggregate forms of amyloid β and, by doing ...

TOKYO and CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

“The parks are our gems,” said Moab resident Mike Coronella. “Our public lands drive the economy here in Moab, and it is insane that they are literally killing the goose that’s laying our ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s drug, Leqembi, after concluding a safety review. The European ...